For research use only. Not for therapeutic Use.
PD-1/PD-L1-IN-13（Cat No.:I044153）is a small-molecule inhibitor designed to disrupt the interaction between Programmed Cell Death Protein 1 (PD-1) and its ligand PD-L1, a critical immune checkpoint pathway exploited by tumors to evade immune responses. By blocking this interaction, PD-1/PD-L1-IN-13 restores T-cell activation and promotes antitumor immunity. It is used in immuno-oncology research to explore alternative therapeutic strategies to monoclonal antibodies, offering potential advantages in oral bioavailability and tissue penetration. PD-1/PD-L1-IN-13 is studied in various cancer models to assess its efficacy in reversing immune suppression and enhancing immunotherapeutic outcomes.
| CAS Number | 2865841-81-0 |
| Synonyms | 4-[[4-chloro-5-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-difluoromethoxy]-2-[[[(3S,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]amino]methyl]phenoxy]methyl]pyridine-2-carbonitrile |
| Molecular Formula | C36H34ClF2N3O9 |
| Purity | ≥95% |
| IUPAC Name | 4-[[4-chloro-5-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]-difluoromethoxy]-2-[[[(3S,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]amino]methyl]phenoxy]methyl]pyridine-2-carbonitrile |
| InChI | InChI=1S/C36H34ClF2N3O9/c1-19-24(21-5-6-27-30(13-21)48-10-9-47-27)3-2-4-25(19)36(38,39)51-29-14-28(49-18-20-7-8-41-23(11-20)15-40)22(12-26(29)37)16-42-32-34(45)33(44)31(17-43)50-35(32)46/h2-8,11-14,31-35,42-46H,9-10,16-18H2,1H3/t31-,32+,33-,34-,35?/m1/s1 |
| InChIKey | TUOSAPKOJRLJAP-JZFXKNFZSA-N |
| SMILES | CC1=C(C=CC=C1C(OC2=C(C=C(C(=C2)OCC3=CC(=NC=C3)C#N)CN[C@H]4[C@H]([C@@H]([C@H](OC4O)CO)O)O)Cl)(F)F)C5=CC6=C(C=C5)OCCO6 |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
